Quanterix Corporation is engaged in fueling scientific discovery through ultra-sensitive biomarker detection. The Company’s Simoa technology delivers earlier biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than the level of quantification (LoQ). Its precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances disease understanding and management in neurology, oncology, immunology, cardiology and infectious disease. Its products and services include Simoa Assay Kits, Simoa Dry Blood Extraction Kit, LDTs & Assay Services, Instruments, Simoa Accelerator Laboratory, Homebrew-Custom Assay Development, and Nova Beads. LDTs & Assay Services include Simoa p-Tau 217, Simoa NfL LDT, and LucentAD pTau 217. Its instruments include Simoa HD-X Analyzer-Automated Immunoassays, Quanterix SR-X Biomarker Detection System, and SP-X Imaging and Analysis System.
Código da empresaQTRX
Nome da EmpresaQuanterix Corp
Data de listagemDec 07, 2017
CEOToloue (Masoud)
Número de funcionários471
Tipo de títulosOrdinary Share
Fim do ano fiscalDec 07
Endereço900 Middlesex Turnpike
CidadeBILLERICA
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal01821
Telefone16173019400
Sitehttps://www.quanterix.com/
Código da empresaQTRX
Data de listagemDec 07, 2017
CEOToloue (Masoud)
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.

Sem dados